688513 Chengdu Easton Biopharmaceuticals
- 55.70
- +0.47+0.85%
Chengdu Easton Biopharmaceuticals News
Chengdu Easton Biopharmaceuticals: Announcement on the Progress of Repurchasing Shares through the Centralized Bidding Trading Method.
Legal Opinion of Beijing Zhide Law Firm on the 2024 Restricted Stock Incentive Plan Adjustment and First Grant of Chengdu Yuandong Biopharmaceutical Co., Ltd.
Chengdu Easton Biopharmaceuticals: Announcement on granting restricted shares for the first time to incentive recipients of the 2024 Restricted Stock Incentive Plan
Chengdu Easton Biopharmaceuticals: List of recipients of incentives granted for the first time in the 2024 Restricted Stock Incentive Plan (as of grant date)
Chengdu Easton Biopharmaceuticals: Audit opinion of the Board of Supervisors on the list of incentive recipients granted for the first time in the Company's 2024 Restricted Stock Incentive Plan (as of the grant date)
Shenzhen Value Online Consulting Co., Ltd. independent financial advisory report on matters relating to the adjustment of the 2024 restricted stock incentive plan and the first grant of Chengdu Yuandong Biopharmaceutical Co., Ltd.
Chengdu Easton Biopharmaceuticals: Announcement of Resolutions of the 19th Meeting of the Third Board of Directors
Chengdu Easton Biopharmaceuticals: Resolutions of the 15th Meeting of the Third Board of Supervisors
Chengdu Easton Biopharmaceuticals: Announcement on matters relating to the adjustment of the 2024 Restricted Stock Incentive Plan
Chengdu Easton Biopharmaceuticals: Notice on Voluntary Disclosure of Beprost Sodium Tablets Obtaining Drug Registration Certificates
Chengdu Easton Biopharmaceuticals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Zhide Law Firm on the 2023 Annual General Meeting of Shareholders of Chengdu Yuandong Biopharmaceutical Co., Ltd.
Chengdu Easton Biopharmaceuticals: 2024 Employee Stock Ownership Plan
Chengdu Easton Biopharmaceuticals: Self-inspection report on the 2024 Restricted Stock Incentive Plan insider's stock trading situation
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Chengdu Yuandong Biopharmaceutical Co., Ltd.
CITIC Securities Co., Ltd. summary report on the continuous supervision and sponsorship of Chengdu Yuandong Biopharmaceutical Co., Ltd.
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Work Site Inspection Report on Chengdu Yuandong Biopharmaceutical Co., Ltd.
Chengdu Easton Biopharmaceuticals: Explanation of the supervisory board's inspection opinions and publicity on the list of incentive recipients granted for the first time in the company's 2024 restricted stock incentive plan
Chengdu Easton Biopharmaceuticals: 2023 Annual General Meeting of Shareholders Meeting Materials
Chengdu Easton Biopharmaceuticals: Announcement on holding the results briefing for the first quarter of 2023 and 2024
Analysis
Price Target
No Data
